¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"peripheral linear enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® peripheral nerve ÇÑ±Û ¸»ÃʽŰæ
¼³¸í   
  ÁßÃ߽Űæ°è¸¦ Á¦¿ÜÇÑ ³ª¸ÓÁö ¸ðµç½Å°æÀ» ¸»ÇÔ. ÁßÃ߽Űæ°è´Â ³ú¿Í Ã´¼ö¸¦ ¸»Çϸç, ±×¿Ü ³ª¸ÓÁö ½Å°æµé·Î½á ½ÇÁ¦ÀûÀ¸·Î °¢ ±â°üÀ̳ª »çÁö ¸»´Ü¿¡ ½Å°æÀÌ ºÐÆ÷Çϸç, ÀÚ±ØÀ» Àü´ÞÇϴ ÀÏÀ» Çϴ ½Å°æÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÃʽŰæÀ̶ó ÇÑ´Ù. ³ú¿¡¼­ ¹Ù·Î ³ª¿Í ºÐÆ÷Çϴ ³ú½Å°æ°ú Ã´¼ö¿¡¼­ ±â½ÃÇϴ ô¼ö½Å°æµµ ¸ðµÎ ¸»ÃʽŰ濡 ÇØ´çÇÑ´Ù. ¶ÇÇÑ ¸»ÃʽŰ濡´Â °¢Á¾ ÀÚÀ²½Å°æÀ» ´ã´çÇϴ ±³°¨½Å°æ, ºÎ±³°¨½Å°æµµ Æ÷ÇԵȴÙ.
¿µ¹® linear accelerator ÇÑ±Û ¼±»ó°¡¼Ó±â
¼³¸í   
  Ä¡·á¹æ»ç¼±°ú¿¡¼­ ÀÌ¿ëÇϴ ±â°è·Î¼­ ÀüÀÚ¸¦ »ý¼ºÇØ ³½´Ù. ÀüÀڴ ´Ü¼øÈ÷ X-¼±°ú´Â ´Ù¸¥ °ÍÀ¸·Î ÀüÀÚ°¡ ±Ý¼Ó¿¡ ºÎµúÇô ³ª¿À´Â °ÍÀÌ X-¼±ÀÌ´Ù. ÀüÀڴ Áø´Ü¸ñÀûº¸´Ù´Â Ä¡·á¸ñÀûÀ¸·Î ÁַΠÇǺÎÀÇ ¾Ç¼ºÁ¾¾ç(¾Ï)¿¡ »ç¿ëµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic enhancement
    ¼Ò¸®Áõ°­, À½ÇâÁõ°­
  • contrast enhancement
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement
    1. ÃËÁø 2. Áõ°­ 3. °­È­
  • enhancement medium
    Áõ°­¹èÁö
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • general linear model
    ÀϹݼ±Çü¸ðµ¨
  • linear
    ÁÙ(¸ð¾ç)-, ¼±Çü-, ¼±»ó-
  • linear acceleration
    ¼±Çü°¡¼Óµµ
  • linear accelerator
    ¼±Çü°¡¼Ó±â
  • linear attenuation coefficient
    ¼±Çü°¨¼è°è¼ö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    Áõ°­, ÁõÁø
  • linear acceleration
    ¼±Çü°¡¼Ó
  • linear fracture
    ¼±°ñÀý
  • linear regression
    ¼±Çüȸ±Í
  • peripheral blood
    ¸»ÃÊÇ÷¾×
  • peripheral conversion
    ¸»ÃÊÀüȯ
  • selective peripheral denervation
    ¼±Åø»ÃʽŰæÂ÷´Ü
  • peripheral neuropathy
    ¸»ÃʽŰ溴Áõ
  • peripheral nerve
    ¸»ÃʽŰæ
  • peripheral
    ¸»ÃÊ-, ÁÖº¯-, ÁÖÀ§
  • peripheral vascular resistance
    ¸»ÃÊÇ÷°üÀúÇ×
  • peripheral nervous system
    ¸»ÃʽŰæ°è, ¸»ÃʽŰæ°èÅë
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • acoustic enhancement
    ¼Ò¸®Áõ°­, À½ÇâÁõ°­
  • contrast enhancement
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • dense enhancement
    °­ÇÑÁ¶¿µÁõ°­
  • enhancement
    Áõ°­, ÁõÁø
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement medium
    Áõ°­¹èÁö
  • immunologic enhancement
    ¸é¿ª±âÇÇÀ¯µµ, ¸é¿ªÃËÁø
  • inflow enhancement
    À¯ÀÔÁõ°­
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • afferent peripheral nerve
    ±¸½É¼º ¸»ÃʽŰæ(¡­ØÇ ãêÌè).
  • glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
  • pulmonary cyst,peripheral
    ¸»Ãʼº(ØÇôþàõ)
  • Linear acceleration
    ¼±»ó°¡¼Ó(àÊ߾ʥáÜ)
  • arrays, linear sequenced
    ¼±Çü ¼øÂ÷ ¹è¿­ (àÊû¡ â÷ó­ ÛÉæê)
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • phased linear array type
    À§»óÂ÷ ¼±Çü ¹è¿­½Ä
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • radiation,linear energy transfer (let)
    ¼±»ó¿¡³ÊÁöÀüȯ(àÊß¾¡­ï®üµ)
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • acoustic enhancement
    À½Çâ Áõ°­
  • immune enhancement
    ¸é¿ªÇÐÀûÃËÁø (Á¾¾çÁõ½ÄÀÇ)
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µÁõ°­
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement ratio
    Á¶¿µ Áõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­ ½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬ Áõ°­
  • enhancement
    Áõ°­
  • enhancement media
    Áõ°­¹èÁö
  • enhancement, immune
    ¸é¿ªÁõ°­Çö»ó
  • enhancement, immunological
    ¸é¿ªÁõ°­Çö»ó
  • flow related enhancement
    À¯µ¿ °ü·Ã Áõ°­
  • immune enhancement
    ¸é¿ªÇÐÀûÃËÁø (Á¾¾çÁõ½ÄÀÇ)
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Peripheral
    ¸»ÃÊ
    [¿¾ ¿ë¾î] ¸»ÃÊ
  • Glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
    [¿¾ ¿ë¾î] ¸»Ãʱ³¼¼Æ÷
  • External zone [Peripheral zone]
    ¹Ù±ùÃþ [ÁÖº¯Ãþ]
    [¿¾ ¿ë¾î] ¿Ü´ë
  • Peripheral zone
    ÁÖº¯±¸¿ª
    [¿¾ ¿ë¾î] ¸»ÃÊ´ë
  • Peripheral zone
    ÁÖº¯±¸¿ª
    [¿¾ ¿ë¾î] ÁÖº¯´ë
  • Peripheral doublet
    ÁÖÀ§¹Ì¼¼°üµÎ¦
    [¿¾ ¿ë¾î] ÁÖÀ§½Ö¹Ì¼Ò°ü
  • Peripheral doublet microtubule
    ÁÖÀ§¹Ì¼¼°üµÎ¦
    [¿¾ ¿ë¾î] ÁÖÀ§½Ö¹Ì¼Ò°ü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral karyosome
    ÁÖÀ§ÇÙ¼Òü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral protein
    ÁÖº¯´Ü¹éÁú(ñ²Ü«Ó±ÛÜòõ)
  • enhancement
    Áõ°­(ñòË­)
  • enhancement effect
    Áõ°­ È¿°ú (ñòË­üùÍý)
  • fluorescence enhancement
    Çü±¤ Áõ°­(û«ÎÃñòË­)
  • immunological enhancement
    ¸é¿ª Áõ°­(Øóæ¹ñòË­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
  • linear absorption coefficient
    ¼±Èí¼ö°è¼ö(àÊýåâ¥Ìõâ¦)
  • linear accelerator
    ¼±Çü°¡¼Ó±â(àÊû¡Ê¥áÜѦ)
  • linear chain
    ¼±Çü(àÊû¡)»ç½½
  • linear correlation
    ¼±Çü »ó°ü(àÊû¡ßÓμ)
  • linear density gradient
    ¼± ¹Ðµµ(à»ÚËÓø)±â¿ï±â
  • linear dichroism
    ¼±Çü ÀÌ»ö¼º(àÊû¡ì£ßäàõ)
  • linear electric field effect
    ¼±Çü Àü±âÀåÈ¿°ú(àÊû¡ï³Ñ¨íÞüùÍý)
  • linear energy transfer
    ¼±Çü(àÊû¡) ¿¡³ÊÁöÀüÀÌ(ï®ì¹)
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • confluent peripheral density
    À¶ÇÕ¼º¸»ÃÊÀ½¿µ
  • peripheral
    ¸»ÃÊ(¼º)ÀÇ
  • peripheral aneurysm
    ¸»Ãʵ¿¸Æ·ù
  • peripheral gating
    ¸»ÃʰÔÀÌÆÃ
  • peripheral interstitial space
    ¸»Ãʰ£Áú°ø°£
  • peripheral nerve
    ¸»ÃʽŰæ
  • peripheral vascular disease
    ¸»ÃÊÇ÷°üÁúȯ
  • acoustic enhancement
    À½ÇâÁõ°­
  • CE [=contrast enhancement]
    Á¶¿µÁõ°­
  • contrast enhancement [=CE]
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬Áõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PV pancreatic vein; papillomavirus; paraventricular; paravertebral; pemphigus vulgaris; peripheral vasc...
PAOD peripheral arterial occlusive disease; peripheral arteriosclerotic occlusive disease
PBL peripheral blood leukocyte; peripheral blood lymphocyte; problem-based learning
PBM peak bone mass; peripheral basement membrane; peripheral blood mononuclear [cell]; placental basemen...
PN papillary necrosis; parenteral nutrition; penicillin; perceived noise; percussion note; periarteriti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ADE Antibody-dependent enhancement
CE Contrast enhancement
ER Enhancement Ratio
EF Enhancement factors
LTE Long-term enhancement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µ Áõ°­
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • peripheral rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement scan
    Á¶¿µ Áõ°­ ½ºÄµ
  • edge enhancement
    °è¸é Áõ°­
  • immunological enhancement
    ¸é¿ª Áõ°­ Çö»ó, ¸é¿ª Áõ°­
    ¸é¿ª ¹ÝÀÀÀÇ ¼öÁØÀ» Áõ´ë½ÃŰ´Â ¿©·¯ °¡Áö ƯÀÌÀû ¶Ç´Â ºñƯÀÌÀû »óȲ.
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µ Áõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • ring enhancement
    ȯ»ó Á¶¿µ Áõ°­
  • sonic enhancement
    À½ÆÄ Áõ°­
  • coefficient of linear thermal expansion
    ¿­ ÆØÃ¢ °è¼ö
    ¹°Ã¼ÀÇ ¿Âµµ¸¦ 1µµ »ó½Â½ÃÅ´¿¡ µû¸¥ ±æÀÌÀÇ Áõ°¡À².
  • fine horizontal linear opacity
    ¹Ì¼¼ÇÑ ¼öÆò¸éÇü ¼±»ó ºÒÅõ¸íü
  • linear
    ¼±»ó, ¼±Çü, ¼±»óÀÇ
    ¼±¿¡ ¼ÓÇϰųª ¼±°ú ´àÀº.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acoustic enhancement A manifestation of increased acoustic signal amplitude returning from regions beyond an object which causes little or no attenuation of the sound beam.
Compare: acoustic shadow.
(05 Mar 2000)
antibody-dependent enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors.
(12 Dec 1998)
radiographic image enhancement Improvement in the quality of an X-ray image by use of an intensifying screen, tube, or filter and by optimum exposure techniques. Digital processing methods are often employed.
(12 Dec 1998)
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
ring enhancement In computed tomography, when a bright circle appears on an image made after injection of contrast medium, characteristic of localization of the contrast in the wall of an abscess.
(05 Mar 2000)
contrast enhancement The intravenous administration of water-soluble iodinated contrast material, which increases the CT number of the vascular pool, as well as some lesions (particularly in the brain), due to abnormal leakage into the interstitium; the property of showing increased radiopacity from concentration of contrast medium.
(05 Mar 2000)
image enhancement Improvement of the quality of a picture by various techniques, including computer processing, digital filtering, echocardiographic techniques, light and ultrastructural microscopy, fluorescence spectrometry and microscopy, scintigraphy, and in vitro image processing at the molecular level.
(12 Dec 1998)
immunological enhancement In immunology, the potentiating effect of specific antibody in establishing and in delaying rejection of a tumour allograft; aside from antibody, non-specific substances may also act to enhance immune response.
Synonym: immunological enhancement.
(05 Mar 2000)
edge enhancement Using analogue or digital image processing to increase the contrast of each interface; equivalent to using a high-pass filter.
(05 Mar 2000)
enhancement Altering an object, substance or site for the improvement of a specific value.
(09 Oct 1997)
enhancement effect Property of higher plant photosynthesis, discovered by Robert Emerson. The quantum yield of red light (less than 680nm) and far red light (700nm), when shone simultaneously on a plant, is greater than the sum of the yields of the light of the two wavelengths separately. This effect provides evidence for the cooperative interaction of two photosystems in photosynthesis.
(18 Nov 1997)
programming, linear A technique of operations research for solving certain kinds of problems involving many variables where a best value or set of best values is to be found. It is most likely to be feasible when the quantity to be optimised, sometimes called the objective function, can be stated as a mathematical expression in terms of the various activities within the system, and when this expression is simply proportional to the measure of the activities, i.e., is linear, and when all the restrictions are also linear. It is different from computer programming, although problems using linear programming techniques may be programmed on a computer.
(12 Dec 1998)
non-linear Not linear.
(05 Dec 1998)
superficial linear keratitis Spontaneous, painful keratitis with epithelial erosion and folds in Bowman's membrane.
(05 Mar 2000)
linear Pertaining to or resembling a line.
Origin: L. Linearis
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    (°¡°Ý,¸Å·Â,°¡Ä¡ µîÀÇ)»ó½Â;µî±Í;Çâ»ó;Áõ´ë
  • revenue enhancement
    ¼¼ÀÔ Áõ°¡(Áõ¼¼¶ó´Â ¸» ´ë½Å ¾²´Â Ç¥Çö)
  • peripheral
    ÁÖÀ§ÀÇ,ÁÖº¯ÀÇ
  • peripheral
    ÁÖÀ§ÀÇ;¸»ÃÊÀÇ;ÁÖº¯ÀûÀÎ;ÁÖº¯ ÀåÄ¡ÀÇ(peripheral nerves ¸»ÃÊ ½Å°æ)
  • peripheral device(unit)
    ÁÖº¯ÀåÄ¡
  • peripheral nervous system
    ¸»ÃÊ ½Å°æ°è
  • linear
    ÁÙÀÇ
  • linear
    Á÷¼±ÀÇ(À¸·Î ÀÌ·ç¾îÁø);¼±ÀÇ
  • linear accelerator
    ¼±Çü°¡¼Ó±â
  • linear measure
    ôµµ
  • linear motor
    ¼±Çü¸ðÅÍ
  • linear programming
    ¼±Çü°èȹ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á